Home
Live Updates
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapibs ... | Region : comparemela.com
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's ... | Region
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers --
Related Keywords
Nevada ,
United States ,
Israel ,
Brooklyn ,
Florida ,
Netherlands ,
Miami ,
Ukraine ,
Russia ,
France ,
Naarden ,
Noord Holland ,
Hannah Deresiewicz ,
Las Vegas ,
Matthew Philippe ,
European Atherosclerosis Society ,
Company Phase ,
Newamsterdam Pharma Companynv Nasdaq ,
Company Contact ,
Neither The Company ,
Securities Exchange Commission ,
National Lipid Association ,
Obicetrapib Treatment Increases Pre Beta ,
Lipophilic Antioxidants ,
Presentation Session Date ,
Obicetrapib Demonstrates Significant Reductions ,
Obicetrapib Alone ,
Ezetimibe Reduces ,
Increased Net Fecal Sterol Excretion ,
Ezetimibe Reduces Atherosclerotic Lesion Size ,
Adipose Tissue ,
Presentation Date ,
Top Of High Intensity ,
Poster Hall Monitor ,
Synergistic Effect ,
Obicetrapib Does Not Accumulate ,
Non Human Primates ,
Unmet Clinical Needs ,
Increased Net Fecal Sterol ,
Presentation Session ,
Amsterdam Pharma ,
Securities Exchange ,
Investor Relations ,
comparemela.com © 2020. All Rights Reserved.